RELATED STUDY
[Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review]
Key Findings: Cannabis-based medicines are not recommended in acute inflammation in active Crohn's disease but can be considered as add-on therapy for abdominal pain and clinically relevant appetite loss.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Germany
Year of Pub: 2024
Cannabinoids Studied: Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Citation: Utz S, et al. [Phytotherapeutic recommendations in medical guidelines for the treatment of gastroenterological diseases - a systematic review]. Z Gastroenterol. 2024; 62:1060-1073. doi: 10.1055/a-2279-5045
Authors: Utz S, Bittel M, Langhorst J
